Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.660
+0.030 (4.76%)
Mar 6, 2026, 10:20 AM EST - Market open
Galmed Pharmaceuticals Employees
As of December 31, 2024, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,450,000
Market Cap
4.34M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| GeoVax Labs | 17 |
| Genprex | 13 |
| BioRestorative Therapies | 11 |
| Indaptus Therapeutics | 7 |
| Oragenics | 5 |
| Acurx Pharmaceuticals | 4 |
| GRI Bio | 4 |
GLMD News
- 4 weeks ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 3 months ago - Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PRNewsWire
- 3 months ago - Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PRNewsWire
- 3 months ago - Galmed Issues CEO Letter to Shareholders - PRNewsWire
- 3 months ago - Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 3 months ago - Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine - PRNewsWire
- 3 months ago - Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - PRNewsWire
- 6 months ago - Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - PRNewsWire